Richard Paul Bryce

All filings by Richard Paul Bryce on record concern Puma Biotechnology, Inc. In total, 54 filings cover trades dated from 9 April 2014 to 5 April 2021.

In open-market terms, that means 2 purchases worth €1,789 on one side and 41 sales worth €4.1M on the other. Sales outweigh purchases by €4.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 6 share grants and 5 option exercises. 2021 to date brings no purchases and 4 sales.

The record was last updated on 6 April 2021 with an open-market sale (€3,532) in Puma Biotechnology, Inc. The latest purchase dates back some time: it was published 4,189 days ago, on 21 May 2015. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.